Clinical trials: Advanced Malignancy, open to volunteers
- Condition Advanced Malignancy
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Advanced Solid Tumors
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
This is an open-label, multicenter, Phase Ib/II clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of FL115 in combination with the anti-PD-1 monoclonal…
- Trial name
- NCT07131202
- Testing
- FL115+PD-1
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Locally Advanced Solid Tumor
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.
- Trial name
- NCT06658353
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.
- Trial name
- NCT06618651
- Testing
- SHR-3821 injection
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study of BPI-460372 in Advanced Solid Tumor Patients
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
- Trial name
- NCT05789602
- Testing
- BPI-460372
- Where
- 11 sites in China
- Volunteers
- 82 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Gastric Cancer
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced…
- Trial name
- NCT05702229
- Testing
- Rilvegostomig, Volrustomig, FOLFOX
- Where
- 44 sites in United States, China and 5 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Advanced Cancer, Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as…
- Trial name
- NCT06656390
- Testing
- ALK201
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 202 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Prostate Cancer
Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology
In recent years, new and promising approaches have emerged in the field of MRI imaging of the prostate. These approaches usually aim to visualise the so-called "microstructures" of the tissue and are intended to offer greater…
- Trial name
- NCT07432360
- Where
- Brazil
- Volunteers
- 300 people
- Sponsor
- Virdx, Inc.
MTAP Deletion
A Study of HS-10587 in Patients With Advanced Solid Tumors
This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy…
- Trial name
- NCT07567859
- Testing
- HS-10587
- Volunteers
- 362 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Locally Advanced or Metastatic Solid Tumor
AZD5305 hADME in Patients With Advanced Solid Malignancies
This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.
- Trial name
- AZD5305 (NCT06713369)
- Testing
- Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose)
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell…
- Trial name
- KYLIN-3 (NCT06970782)
- Testing
- Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatin
- Volunteers
- 278 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close…
- Trial name
- NCT04802759
- Testing
- Giredestrant, Abemaciclib, Ipatasertib
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 316 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid…
- Trial name
- NCT05907980
- Testing
- ROSE12, Atezolizumab, Pembrolizumab
- Where
- 14 sites in United States, Japan
- Volunteers
- 209 people
- Sponsor
- Chugai Pharmaceutical
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
Breast Cancer, Solid Tumor
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Trial name
- NCT06503783
- Testing
- BL-M17D1
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors Cancer
First-In-Human Study of KHN922 for Injection
A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
- Trial name
- NCT07514975
- Testing
- KHN922 for injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.